DC101-CP132單克隆抗體是原始DC101單克隆的重組嵌合型抗體。可變結(jié)構(gòu)域序列與原始DC101相同，但是恒定區(qū)序列已經(jīng)從大鼠IgG1變?yōu)樾∈驣gG2a。DC101-CP132單克隆抗體像原始大鼠IgG1抗體一樣，不包含F(xiàn)c突變。
DC101-CP132單克隆抗體能與小鼠VEGFR-2(血管內(nèi)皮生長(zhǎng)因子受體2)反應(yīng)，VEGFR-2也稱為CD309、KDR和Flk-1。VEGFR-2是酪氨酸蛋白激酶家族的成員。當(dāng)結(jié)合到其配體血管內(nèi)皮生長(zhǎng)因子時(shí)發(fā)揮生理作用，血管內(nèi)皮生長(zhǎng)因子受體-2在血管發(fā)育和通透性中起關(guān)鍵作用。血管內(nèi)皮生長(zhǎng)因子受體-2在成人心臟、肺、腎、腦和骨骼肌的內(nèi)皮細(xì)胞中高表達(dá)，在其他組織中低表達(dá)。DC101單克隆抗體已被證明在體內(nèi)抑制VEGFR-2信號(hào)傳導(dǎo)。
產(chǎn)品詳情：
|
產(chǎn)品名稱 |
RecombiMAb anti-mouse VEGFR-2 |
|
產(chǎn)品貨號(hào) |
CP132 |
|
產(chǎn)品規(guī)格 |
1/5/25/50/100mg |
|
反應(yīng)種屬 |
Mouse |
|
克隆號(hào) |
DC101-CP132 |
|
同種型 |
Mouse IgG2a(switched from rat IgG1) |
|
免疫原 |
Mouse VEGFR-2-SEAPs soluble receptor |
|
實(shí)驗(yàn)應(yīng)用 |
in vivo blocking of VEGF/VEGFR-2 signaling* |
|
產(chǎn)品形式 |
PBS, pH 7.0,Contains no stabilizers or preservatives |
|
純度 |
>95%, Determined by SDS-PAGE |
|
聚合 |
<5%, Determined by SEC |
|
無(wú)菌處理 |
0.2 µm filtration |
|
純化方式 |
Protein G |
|
分子量 |
150 kDa |
|
小鼠病原檢測(cè) |
Ectromelia/Mousepox Virus: Negative Hantavirus: Negative K Virus: Negative Lactate Dehydrogenase-Elevating Virus: Negative Lymphocytic Choriomeningitis virus: Negative Mouse Adenovirus: Negative Mouse Cytomegalovirus: Negative Mouse Hepatitis Virus: Negative Mouse Minute Virus: Negative Mouse Norovirus: Negative Mouse Parvovirus: Negative Mouse Rotavirus: Negative Mycoplasma Pulmonis: Negative Pneumonia Virus of Mice: Negative Polyoma Virus: Negative Reovirus Screen: Negative Sendai Virus: Negative Theiler’s Murine Encephalomyelitis: Negative |
|
保存條件 |
抗體原液保存在4°C，不能冷凍保存。 |
|
推薦同型對(duì)照 |
InVivoPlus mouse IgG2a isotype control, unknown specificity（貨號(hào)BP0085） |
|
推薦抗體稀釋液 |
InVivoPure pH 7.0 Dilution Buffer（貨號(hào)IP0070） |
該產(chǎn)品自上市已被多篇SCI文獻(xiàn)引用，品質(zhì)有保證，以下是部分已發(fā)表的文獻(xiàn)引用：
|
應(yīng)用 |
文章 |
|
體內(nèi)VEGF/VEGFR-2 信號(hào)阻斷 (in vivo blocking of VEGF/VEGFR-2 signaling) |
1. Ding, X., et al. (2015). 'Distinct functions of epidermal and myeloid-derived VEGF-A in skin tumorigenesis mediated by HPV8' Cancer Res 75(2): 330-343.
2. Lee, H. J., et al. (2015). 'Inhibition of vascular endothelial growth factor A and hypoxia-inducible factor 1alpha maximizes the effects of radiation in sarcoma mouse models through destruction of tumor vasculature' Int J Radiat Oncol Biol Phys 91(3): 621-630.
3. Arulanandam, R., et al. (2015). 'VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection' Cancer Cell 28(2): 210-224.
4. Kizhatil, K., et al. (2014). 'Schlemm’s canal is a unique vessel with a combination of blood vascular and lymphatic phenotypes that forms by a novel developmental process' PLoS Biol 12(7): e1001912. |
|
體內(nèi)VEGF/VEGFR-2信號(hào)阻斷， 體外VEGFR信號(hào)阻斷 (in vivo blocking of VEGF/VEGFR-2 signaling, in vitro blocking of VEGFR signaling) |
1.Larrayoz, M., et al. (2014). 'Contrasting responses of non-small cell lung cancer to antiangiogenic therapies depend on histological subtype' EMBO Mol Med 6(4): 539-550. |
更多產(chǎn)品詳情請(qǐng)咨詢 BioXCell 中國(guó)授權(quán)代理——欣博盛生物
全國(guó)服務(wù)熱線: 4006-800-892 郵箱: market@neobioscience.com
深圳: 0755-26755892 北京: 010-88594029
廣州：020-87615159 上海: 021-34613729
代理品牌網(wǎng)站: www.neobioscience.com
自主品牌網(wǎng)站: www.neobioscience.net